Expected news for Q4 202019 Nov 2020 09:57
From recent Q&A on Directors Talk:
"We’re starting our COVID proof of concept in vivo work imminently and that’s for our un-optimised version of the Nuvec system so once we have this data, we shouldn’t take too long, we will then look to do another follow on in vivo study with optimised versions of the product. So, we’re running the optimisation work in parallel to that first study so that we can then pull all the learnings together to come up with a further proof of concept work because the continued updates of the work as we go, enables us to keep reaching out to people to say, this is how Nuvec works.
So, investors can expect a lot more news on both the COVID proof of concept work and the optimisation work and well also be updating progress on the oral programme as soon as we get it, as it goes forward.
Finally, we’ll give an update on other applications, on top of both oral and injectable vaccines, that we see and will be a priority for the development of Nuvec".